Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma

Wei Jiang(China Electronics Technology Group Corporation), Jun Ma(Shanghai Institute of Technology)

Cell Reports Medicine

June 1, 2024

10.1016/j.xcrm.2024.101594

Cited by 25

Related Papers

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

|New England Journal of Medicine|2019|934

A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy

|PLoS ONE|2012|703

Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma

|Cell Research|2020|483

Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3

|Cancer Research|2019|423

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

|The Lancet|2021|234